HighTower Advisors
IMVT icon

HighTower Advisors’s Immunovant IMVT Stock Holding History

HighTower Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000
Closed -$182 – 3893
2024
Q4 		$182 Hold
1,000
– – ﹤0.01% 3766
2024
Q3 		$2.17K Buy
+1,000
New +$29.5K ﹤0.01% 3629

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

HighTower Advisors's IMVT Position: Q1 2026 in Review

HighTower Advisors increased its Immunovant (IMVT) stake by 70% in Q1 2026, buying an estimated $604K and bringing the position to 56,744 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1950.

HighTower Advisors first reported a position in IMVT in Q4 2020 and has held it in 19 quarters since. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • HighTower Advisors held 56,744 shares of Immunovant worth $1.41M as of Q1 2026.
  • HighTower Advisors bought 23,336 Immunovant shares in Q1 2026, an estimated $604K.
  • Immunovant made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #1950 holding.
  • HighTower Advisors first reported a position in Immunovant in Q4 2020 and has held it in 19 quarters since.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.